Gil Roth11.20.13
Phase II
Advaxis starts HPV cancer trial . . . read more
Amgen presents PCSK9 LDL results . . . read more
CytRx starts GBM trial . . . read more
Zealand begins danegaptide POC trial . . . read more
Phase III
Daiichi's edoxaban exceeds warfarin targets . . . read more
Filings
Health Canada approves Sanofi's Aubagio . . . read more
Launches
Cornerstone launches Bethkis for CF . . . read more
Advaxis starts HPV cancer trial . . . read more
Amgen presents PCSK9 LDL results . . . read more
CytRx starts GBM trial . . . read more
Zealand begins danegaptide POC trial . . . read more
Phase III
Daiichi's edoxaban exceeds warfarin targets . . . read more
Filings
Health Canada approves Sanofi's Aubagio . . . read more
Launches
Cornerstone launches Bethkis for CF . . . read more